The natural history of multiple sclerosis: A geographically based study: 4. APPLICATIONS to PLANNING and INTERPRETATION of CLINICAL therapeutic trials

Brain

Volumn 114, Issue 2, 1991, Pages 1057-1067

  Weinshenker, B G ^a   Rice, G P A ^a   Noseworthy, J H ^a   Carriere, W ^a   Baskerville, J ^a   Ebers, G C ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

CLINICAL TRIALS; FEMALE; FOLLOW-UP STUDIES; GEOGRAPHY; HUMAN; MALE; MULTIPLE SCLEROSIS; ONTARIO; RESEARCH DESIGN; SUPPORT, NON-U.S. GOV'T;

EID: 0025728367     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/114.2.1057     Document Type: Article

References (17)

1. British and Dutch Multiple Sclerosis Azathioprine Trial Group (1988) Double-masked trial of azathioprine in multiple sclerosis. Lancet 11, 179-183
2. Donner A (1984) Approaches to sample size estimation in the design of clinical trials-a review. Statistics in Medicine, 3, 199-214
3. Eluson GW, Myers LW, Mickey MR, Graves MC, Tourtellotte WW, Syndulko K et al. (1989) A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine withand without méthylprednisolone in multiple sclerosis. Neurology, Cleveland, 39, 1018-1026
4. Fleiss JL (1981) Statistical Methods for Rates and Proportions. Second edition. Edited by J. L. Fleiss. New York and Chichester: John Wiley, pp. 212-236
5. Hauser SL, Dawson DM, Lehrich JR, Beal MF, Kevy SV, Propper RD et al. (1983) Intensive immunosuppression in progressive multiple sclerosis: a randomized, three-arm study of high-doseintravenous cyclophosphamide, plasma exchange, and ACTH. New England Journal of Medicine, 308, 173-180
6. Kappos L, Patzold U, Dommasch D, Poser S, Haas J, Krauseneck P et al. (1988) Cyclosporine versus azathioprine in the long-term treatment of multiple sclerosis-results of the German multicenter study.Annals of Neurology, 23, 56 - 63
7. Kurtzke JF (1961) On the evaluation of disability in multiple sclerosis. Neurology, Minneapolis, II, 686-694
8. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology, Cleveland, 33, 1444-1452
9. Kurtzke JF (1986) Neuroepidemiology. Part II: assessment of therapeutic trials. Annab of Neurology, 19, 311-319
10. Miller AE, Bornstein M, Slagle S, Crystal H, Drexler E, Keilson M et al. (1989) Clinical trial of Cop 1 in chronic-progressive multiple sclerosis. Neurology, Cleveland, 39, Supplement 1, 356-357
11. Noseworthy JH and The Canadian Cooperative Multiple Sclerosis Study Group (1988) Concordance between examining neurologists on multiple sclerosis disability scales in a blinded, prospective clinical trial. Neurology, Cleveland, 38, Supplement 1, 195
12. Nuwer MR, Packwood JW, Myers LW, Eluson GW (1987) Evoked potentials predict the clinical changes in a multiple sclerosis drug study. Neurology, Cleveland, 37, 1754-1761
13. Paty DW (1988) Trial measures in multiple sclerosis: the use of magnetic resonance imaging in the evaluation of clinical trials. Neurology, Cleveland, 38, Supplement 2, 82-83
14. Weinshenker, BG, Bass B, Rice GPA, Noseworthy J, Carrière W, Baskerville J et al. (1989a) The natural history of multiple sclerosis: a geographically based study. 1. Clinical course and disability.Brain, 112, 133-146
15. Weinshenker BG, Bass B, Rice GPA, Noseworthy J, Carrière W, Baskerville J et al. (19896) The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of theearly clinical course. Brain, 112, 1419-1428
16. Weinshenker BG, Rice GPA, Noseworthy JH, Carrière W, Baskerville J, Ebers GC (1991) The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictivefactors and models of outcome. Brain, 114, 1045 - 1056
17. Zar JH (1984) Biostatistical Analysis. Englewood Cliffs, NJ: Prentice-Hall, pp. 323-325